Breaking News Instant updates and real-time market news.

ORCL

Oracle

$39.09

0.81 (2.12%)

, N

Acquired by ORCL

$90.34

(0.00%)

16:56
11/07/16
11/07
16:56
11/07/16
16:56

On The Fly: Top stock stories for Monday

Stocks began the day sharply higher and the major averages continued to add to their gains from there, finishing with an advance of about 2%. In the process, the S&P broke its nine-day losing streak. Based on today's action the market is pricing in a Clinton presidential victory and a maintenance of the status quo in Washington. Oil prices moved higher as well and closed with gains of almost 2% while U.S. benchmark WTI crude broke its own six-day losing streak. ECONOMIC NEWS: In the U.S., the Fed's labor market conditions index rose 0.7 points in October following a revised 0.1 point decline in September. September Consumer Credit came in at $19.3B, above consensus estimates of $18.7B for the month. In Europe, Eurozone retail sales edged down by 0.2% in September, led by a decline in Germany. COMPANY NEWS: Oracle (ORCL) announced that it has secured enough shares to complete its tender offer for NetSuite (N) despite opposition from shareholder T. Rowe Price (TROW), which had argued that the $109 per share bid significantly undervalued the company. The buyout deal will be finalized on Monday, Oracle said... Shares of Biogen (BIIB) gained 6.7% after the company and partner Ionis Pharmaceuticals (IONS) said a Phase 3 study of their muscular disorder treatment, SPINRAZA, met its primary endpoint. Earlier this morning, Piper Jaffray analyst Joshua Schimmer had upgraded Biogen to Overweight, before the data was announced. Meanwhile, Ionis' stock advanced 18.4% following the announcement... Shares of LendingClub (LC) rose about 15% after the online lender secured a new loan-sale deal and its third quarter results beat expectations. MAJOR MOVERS: Among the notable gainers was Sysco (SYY), which advanced 9.8% after the foodservice distributor reported better than expected first quarter results. Also higher was Blue Nile (NILE), which jumped nearly 34% to $40.76 after the luxury jeweler announced it plans to be acquired by private equity firm Bain capital and Bow Street for $500M. Additionally, Sothebys (BID) rose 11.2% after the auction house operator announced mixed results for the third quarter, with its CEO Tad Smith pointing out that the art advisory business "has added a number of clients and has a rich pipeline of discussions for future growth." Among the noteworthy losers was HSN, Inc. (HSNI), which fell over 13% after the parent company of the Home Shopping Network reported disappointing third quarter results. Also lower was EarthLink (ELNK), which slid 10% after the company and Windstream Holdings (WIN) announced that their boards of directors have unanimously approved a definitive merger agreement, under which they will merge in an all-stock transaction valued at approximately $1.1B, including debt. Upon closing of the transaction, Windstream shareholders will own approximately 51% and EarthLink shareholders will own approximately 49% of the combined company. Additionally, Coherus Biosciences (CHRS) dropped 9% after the company announced that it has received a decision from the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office denying institution of Coherus' petition for Inter Partes Review of AbbVie's (ABBV) U.S. Patent '166 related to the latter's Humira formulation. INDEXES: The Dow rose 371.32, or 2.08%, to 18,259.60, the Nasdaq gained 119.80, or 2.37%, to 5,166.17, and the S&P 500 advanced 46.34, or 2.22%, to 2,131.52.

ORCL

Oracle

$39.09

0.81 (2.12%)

N

Acquired by ORCL

$90.34

(0.00%)

TROW

T. Rowe Price

$64.33

0.63 (0.99%)

BIIB

Biogen

$295.62

18.62 (6.72%)

IONS

Ionis Pharmaceuticals

$32.12

4.99 (18.39%)

LC

LendingClub

$5.91

0.78 (15.20%)

SYY

Sysco

$52.76

4.72 (9.83%)

NILE

Taken private

$40.76

10.32 (33.90%)

BID

Sotheby's

$38.43

3.87 (11.20%)

HSNI

HSN, Inc.

$31.25

-4.75 (-13.19%)

ELNK

EarthLink

$5.60

-0.62 (-9.97%)

WIN

Windstream

$7.23

-0.01 (-0.14%)

CHRS

Coherus Biosciences

$25.60

-2.55 (-9.06%)

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 09

    Nov

  • 09

    Nov

  • 10

    Nov

  • 14

    Nov

  • 16

    Nov

  • 16

    Nov

  • 16

    Nov

  • 29

    Nov

  • 05

    Dec

  • 13

    Dec

  • 14

    Dec

ORCL Oracle
$39.09

0.81 (2.12%)

09/23/16
STFL
09/23/16
NO CHANGE
STFL
Oracle removed from Select List at Stifel
After attending Oracle's Analyst Day, Stifel analyst Brad Reback says that the company's infrastructure as a service portfolio "is still quite nascent." The analyst thinks that the company will have to significantly raise its overall capex in order to catch up with the leaders in the space. The analyst trimmed his price target on the stock to $45 from $48 and removed the stock from his Select List. However, he keeps a Buy rating on the shares.
09/16/16
BERN
09/16/16
NO CHANGE
BERN
Oracle miss due to 'transitory issues,' says Bernstein
After Oracle reported weaker than expected Q1 results, Bernstein analyst Mark Moerdler blames the miss on "transitory" factors, including foreign exchange headwinds and increased borrowing costs, as well as weakness in businesses on which the company is "less concerned with." The analyst says that the company's cloud business exceeded expectations, and he notes that its overall software revenue increased last quarter. He keeps an Outperform rating on the shares.
09/16/16
ADAM
09/16/16
NO CHANGE
Target $45
ADAM
Buy
Oracle shares cheap, cloud results positive, says Canaccord
Canaccord analyst Richard Davis said Oracle reported solid organic growth for its cloud business, including software licenses and cloud SaaS and PaaS. The analyst believes continued cloud success will weigh on margins and the decline in Hardware revenues will weigh on the overall businesses. However, Davis said Oracle shares remain sufficiently inexpensive to maintain as a Buy with a $45 price target.
09/16/16
RHCO
09/16/16
NO CHANGE
RHCO
Oracle reported 'strong cloud results,' says SunTrust
SunTrust analyst John Rizzuto says that Oracle reported "strong cloud results." The analyst thinks that the company's cloud business is gaining "market and mind share." He predicts that the company's combined cloud and on-premises software revenue will rise 5% in fiscal 2017, up from a 2% decline in fiscal 2016. He keeps a $48 price target and Buy rating on the stock.
N Acquired by ORCL
$90.34

(0.00%)

10/26/16
10/26/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Mylan (MYL) initiated with a Buy at Mizuho. 2. Five Below (FIVE) initiated with a Buy at Longbow. 3. NetSuite (N) reinstated with an Underperform at BofA/Merrill. 4. Adient (ADNT) initiated with a Buy at Northcoast. 5. Party City (PRTY) initiated with a Neutral at Goldman. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/28/16
DADA
10/28/16
DOWNGRADE
DADA
Underperform
NetSuite downgraded to Underperform from Neutral at DA Davidson
10/26/16
BOFA
10/26/16
INITIATION
Target $68
BOFA
Underperform
NetSuite reinstated with an Underperform at BofA/Merrill
BofA/Merrill analyst Kash Rangan reinstated NetSuite (N) with an Underperform with a $68 price target from No Rating.
09/13/16
JMPS
09/13/16
NO CHANGE
JMPS
NetSuite takeover price likely to increase, says JMP Securities
JMP Securities analyst Patrick Walravens believes that Oracle's (ORCL) $109 takeover offer for NetSuite (N) will probably increase, partly because a majority of shares owned by those who are not insiders must vote to approve the transaction. The analyst notes that T. Rowe Price (TROW), which controls 18% of such shares, opposes the deal at the current price. Walravens adds that NetSuite appears to have failed to "canvas the market," as required by Delaware law. He raised his price target on NetSuite to $121 from $100 and keeps an Outperform rating on the stock.
TROW T. Rowe Price
$64.33

0.63 (0.99%)

06/02/16
UBSW
06/02/16
UPGRADE
UBSW
Buy
Envestnet upgraded to Buy from Neutral at UBS
UBS analyst Brennan Hawken upgraded Envestnet to Buy saying the company is one of the few beneficiaries of the Department of Labor's fiduciary rule. Hawken this morning also downgraded Franklin Resources (BEN) to Sell and Invesco (IVZ) to Neutral. He also lowered his estimates for BlackRock (BLK) and T. Rowe Price (TROW).
07/20/16
DBAB
07/20/16
DOWNGRADE
Target $75
DBAB
Hold
T. Rowe Price downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Brian Bedell downgraded T. Rowe Price to Hold saying the company's net flows may become challenged over the next few quarters after three quarters of improving organic growth. T. Rowe's one-year relative fund performance has eased, Bedell tells investors in a research note. He cut his price target for the shares to $75 from $79.
06/16/16
JEFF
06/16/16
NO CHANGE
Target $13
JEFF
Buy
WisdomTree takeover more likely amid negative growth, says Jefferies
Jefferies analyst Surinder Thind says WisdomTree's currency hedged flagship funds DXJ and HEDJ continue to "outflow at an elevated pace" as amid unfavorable global central bank policies. It is not possible to predict the level of assets under management these funds will bottom out at, Thind tells investors in a research note. He believes, however, that continued negative growth increases the likelihood of WisdomTree becoming an acquisition target. The analyst keeps a Buy rating on the shares with a $13 price target. He believes Franklin Resources (BEN) and T. Rowe Price (TROW) could have interest in the company.
BIIB Biogen
$295.62

18.62 (6.72%)

11/07/16
MZHO
11/07/16
INITIATION
Target $290
MZHO
Neutral
Biogen initiated with a Neutral at Mizuho
Mizuho analyst Salim Syed initiated Biogen with a Neutral rating and a $290 price target.
11/07/16
11/07/16
UPGRADE
Target $365

Outperform
Biogen upgraded to Outperform at Leerink
As previously reported, Leerink analyst Geoffrey Porges upgraded Biogen to Outperform from Market Perform following the positive interim data for CHERISH, a Phase 3 study of Spinraza for the treatment of later-onset spinal muscular atrophy or SMA. While the positive outcome of this trial did not come as a surprise to the analyst, the timing was "much earlier" than the company's guidance and his expectations. He notes that both the timing and result materially increases the assurance that the initial label will include all or at least most forms of SMA, giving the drug even more near term revenue potential than modelled previously. The analyst also raised his price target on the shares to $365 from $361.
11/07/16
LEER
11/07/16
UPGRADE
LEER
Outperform
Biogen upgraded to Outperform from Market Perform at Leerink
11/07/16
11/07/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Time Warner (TWX) upgraded to Outperform from Neutral at Credit Suisse with analyst Omar Sheikh citing attractive valuation. 2. Waste Management (WM) upgraded to Overweight from Equal Weight at Barclays with analyst Jon Windham saying the recent pullback in shares provides a buying opportunity given the company's "strong" underlying fundamentals. 3. Parker-Hannifin (PH) upgraded to Buy from Hold at Evercore ISI and to Overweight from Equal Weight at Morgan Stanley. 4. Biogen (BIIB) upgraded to Overweight from Neutral at Piper Jaffray with analyst Joshua Schimmer saying the company still has time to "get its act together to maximize the value of its SMA franchise, and stop being M&A disciplined/pipeline-undisciplined." 5. Cummins (CMI) upgraded to Buy from Hold at Evercore ISI with analyst David Raso citing lowered expectations, valuation, and accelerating inflation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
IONS Ionis Pharmaceuticals
$32.12

4.99 (18.39%)

11/07/16
PIPR
11/07/16
NO CHANGE
PIPR
Biogen, Ionis get jump start on AveXis, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says that following his upgrade this morning, Biogen (BIIB) and its partner Ionis Pharmaceuticals (IONS) announced that a Phase III study of nusinersen met its primary endpoint. The data look "very good," Schimmer tells investors in a research note. This gives Biogen and Ionis a jump start on rival gene therapy player AveXis for the Type II/III setting, Schimmer tells investors in a research note. If not for competition from AveXis, nusinersen would become a $5B-plus mega-blockbuster by addressing one of the highest unmet needs in pediatric diseases that exists today, the analyst contends. Schimmer believes, however, that AveXis is moving quickly to compete in the market. The analyst still hopes Biogen "will find a way to partner" with AveXis. He still thinks nusinersen, which is now called SPINRAZA, can achieve $1B-$2B-plus in peak annual revenue. Following this morning's upgrade, Schimmer has an Overweight rating on Biogen with a $335 price target.
11/01/16
PIPR
11/01/16
NO CHANGE
PIPR
Overweight
Piper sees thrombosis treatment from Ionis as differentiated
Piper Jaffray analyst Joshua Schimmer believes IONS-FXI is differentiated by its "potential utility in renal impairment, infrequent injections and low risk of bleeding complications." Ionis Pharmaceuticals (IONS) and its partner Bayer (BAYRY) reported positive data from a Phase 2 study of IONS-FXI, an anti-clotting antisense therapeutic which targets Factor 11 to prevent thrombosis, Schimmer tells investors in a research note. He views the recent weakness in Ionis shares as a "compelling buying opportunity" and reiterates an Overweight rating on the name.
10/10/16
WELS
10/10/16
NO CHANGE
WELS
Ionis drug likely to be approved rapidly, says Wells Fargo
After Ionis Pharmaceuticals (IONS) and partner Biogen (BIIB) reported detailed data for their RNA Therapeutic nusinersen, in patients with both symptomatic and pre-symptomatic type 1 Spinal Muscular Atrophy, as well as data for patients with type 2/3 Spinal Muscular Atrophy, or SMA, Wells Fargo says it expects the drug to be rapidly approved. The firm thinks that the FDA will approve "a broad label" covering pre-symptomatic and symptomatic type I SMA, as well as type 2/3 SMA. The firm says that the companies should have "a very large commercial opportunity," and it keeps an Outperform rating on Ionis.
11/07/16
JPMS
11/07/16
NO CHANGE
JPMS
Neutral
JPMorgan still views Ionis as fairly valued
JPMorgan analyst Jessica Fye believes the data today continue to "derisk and solidify" Spinraza's clinical profile. The analyst, however, thinks it will be difficult to lift the overhang around platelet adverse events. She continues to view Ionis Pharmaceuticals as fairly valued and keeps a Neutral rating on the shares. Ionis is up 18% to $32.10 in afternoon trading.
LC LendingClub
$5.91

0.78 (15.20%)

11/03/16
MSCO
11/03/16
UPGRADE
MSCO
Overweight
LendingClub upgraded to Overweight from Equal Weight at Morgan Stanley
10/28/16
CHLM
10/28/16
UPGRADE
Target $6.75
CHLM
Buy
LendingClub upgraded to Buy from Hold at Craig-Hallum
Craig-Hallum analyst Bradley Berning upgraded LendignClub to Buy following recent channel checks that indicate increased bank channel volumes. Berning's contacts confirm that the Bank Channel is signing back up with LendingClub, with one key bank partner returning in Q4. His data indicates October has started above Q3's average and the analyst has increased confidence in his 2017 estimate. Berning believes risk/reward in LendingClub shares has turned positive ahead of the Q3 report on November 7 and views a more positive discussion on the bank channel as a catalyst.
11/03/16
11/03/16
UPGRADE
Target $7

Overweight
LendingClub upgraded to Overweight on sustainable growth at Morgan Stanley
As previously reported, Morgan Stanley upgraded LendingClub to Overweight from Equal Weight with a $7 price target. Analyst James Faucette said LendingClub shares are inexpensive and its recent developments/investor survey indicates a stable outlook. The analyst believes new management is the right blend to get business on track and restore investor confidence and said feedback indicates stable capital availability for 2017.
11/03/16
11/03/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Transocean (RIG) upgraded to Buy from Hold at Canaccord with analyst Alex Brooks noting the company reported very strong third quarter results due to its cost cutting efforts. 2. U.S. Steel (X) upgraded to Neutral from Underperform at BofA/Merrill and to Neutral from Sell at Clarksons Platou. 3. Targa Resources (TRGP) upgraded to Buy from Hold at Stifel with analyst Selman Akyoi citing what he sees as strong fourth quarter export guidance by the company as the primary reason for the upgrade. 4. LendingClub (LC) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst James Faucette saying LendingClub shares are inexpensive and its recent developments/investor survey indicates a stable outlook. 5. Finish Line (FINL) upgraded to Positive from Neutral at Susquehanna with analyst Sam Poser saying he views reports the company is looking to sell JackRabbit as a positive development and believes the company will benefit greatly from its added focus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SYY Sysco
$52.76

4.72 (9.83%)

09/26/16
WELS
09/26/16
NO CHANGE
WELS
Sysco weakness creates buying opportunity, says Wells Fargo
After meeting with Sysco's management, Wells Fargo says the company "remains well-positioned for local customer growth, share gains, and improved profitability over the long-term." The firm blames the stock's recent retreat on "macro/yield factors, renewed deflation concerns and recent end market deceleration." However, it thinks the company is "well-equipped" to deal with deflation and it believes that independent restaurants' growth is outpacing that of chains. Wells thinks that Sysco's stock has reached an attractive entry point.
09/23/16
LEHM
09/23/16
INITIATION
Target $48
LEHM
Underweight
Sysco initiated with an Underweight at Barclays
Barclays analyst Karen Short started Sysco with an Underweight rating and $48 price target.
07/18/16
07/18/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Twilio (TWLO) initiated with a Neutral at Goldman, an Outperform at William Blair, a Hold at Canaccord, a Sector Weight at Pacific Crest, a Market Perform at JMP Securities, and with a Neutral at JPMorgan. 2. Selecta Biosciences (SELB) initiated with a Buy at UBS, a Buy at Stifel, a Buy at Canaccord, and a Buy at Needham. 3. China Mobile (CHL) and China Telecom (CHA) assumed with a Buy at Jefferies. 4. NetEase (NTES) initiated with a Buy at Brean Capital. 5. Sysco (SYY) reinstated with a Hold at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NILE Taken private
$40.76

10.32 (33.90%)

02/11/16
BOFA
02/11/16
DOWNGRADE
Target $21
BOFA
Blue Nile downgraded to Underperform from Buy at BofA/Merrill
As previously reported, BofA Merrill Lynch analyst Paul Bieber downgraded Blue Nile two notches, to Underperform from Buy, and cut his price target on the stock to $21 from $42 after the company's earnings report, citing diamond price volatility leading to lower average selling prices, the softness in the high-end market, and the potential tax implications of its plans to open physical locations.
12/08/15
12/08/15
INITIATION

Sector Weight
Blue Nile initiated with a Sector Weight at Pacific Crest
Pacific Crest analysts started Blue Nile with a Sector Weight rating.
02/12/16
SPHN
02/12/16
NO CHANGE
Target $28
SPHN
Overweight
Blue Nile expectations dramatically lower after selloff, says Stephens
Stephens analyst Rick Patel said Blue Nile's pricing infrastructure becomes a detriment when diamond prices fall too steeply, as seen in its Q4 results, but also enables it to capture market share when prices are soft. Patel lowered his price target on the stock to $28 from $40, but keeps an Overweight rating on shares following yesterday's post-earnings slide, saying that expectations are now dramatically lower, there are early signs that diamond prices may be stabilizing and that the company's new guidance appears achievable.
06/10/16
WBLR
06/10/16
INITIATION
WBLR
Market Perform
Blue Nile initiated with a Market Perform at William Blair
William Blair analyst Ryan Domyancic started Blue Nile with a Market Perform rating. The analyst believes revenue growth needs to show sustainable reacceleration in order for shares to rally.
BID Sotheby's
$38.43

3.87 (11.20%)

08/09/16
COWN
08/09/16
NO CHANGE
Target $36
COWN
Market Perform
Sotheby's price target raised to $36 from $28 at Cowen
Cowen raised its price target on Sotheby's to $36 from $28 citing encouraging strategic initiatives focused on driving solid auction commission margins and judicial use of guarantees. Cowen maintained its Market Perform rating on Sotheby's shares.
04/14/16
STPT
04/14/16
DOWNGRADE
STPT
Hold
Sotheby's downgraded to Hold from Buy at Standpoint Research
02/26/16
BRRR
02/26/16
DOWNGRADE
BRRR
Market Perform
Sotheby's downgraded on slowing demand, employee losses at Barrington
As previously reported, Barrington analyst Kristine Koerber downgraded Sotheby's to Market Perform from Outperform, citing the company's loss of some senior employees, which she believes could result in a loss of important relationships and business, as well as slowing demand in the high-end art market.
02/26/16
BRRR
02/26/16
DOWNGRADE
BRRR
Market Perform
Sotheby's downgraded to Market Perform from Outperform at Barrington
HSNI HSN, Inc.
$31.25

-4.75 (-13.19%)

10/06/16
SBSH
10/06/16
DOWNGRADE
Target $43
SBSH
Neutral
HSN, Inc. downgraded to Neutral from Buy at Citi
Citi analyst Jason Bazinet downgraded HSN, Inc. (HSNI) to Neutral saying the company's business has been "slowly deteriorating." Unlikely Liberty Interactive (QVCA), HSN has not been using credit "to paper over" the underlying top-line deterioration, Bazinet tells investors in a research note. He now believes HSN shares may only reach $43 in 2018, suggesting less than 10% upside. The analyst lowered his price target for the shares to $43 from $53. Bazinet keeps a Buy rating on Liberty Interactive but lowered his price target for the shares to $26 from $33.
10/31/16
MAXM
10/31/16
NO CHANGE
Target $61
MAXM
Buy
HSN, Inc. shares oversold amid short-term challenges, says Maxim
Maxim analyst Tom Forte acknowledge that his above-consensus projections for HSN, Inc.'s Q3 results may be "relatively optimistic" given that the Summer Olympics and election may have disrupted HSN's operating results. However, he believes the challenges facing the company to be widely known and views the shares as oversold given his expectation for significant upside over the next 12 months. Forte keeps a Buy rating and $61 price target on HSN shares ahead of the company's report on November 7.
10/10/16
10/10/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Honeywell (HON) downgraded to Buy from Conviction Buy at Goldman with analyst Christopher Glynn lowering his Q3 Earnings Per Share expectations for Honeywell after the company cut its earnings and revenue outlook and trimmed his price target to $122 from $128. 2. United Technologies (UTX) downgraded to Neutral from Buy at Citi with analyst Jason Gursky saying he sees three issues limiting share upside over the next twelve-plus months. 3. PNC Financial (PNC) was downgraded to Neutral from Buy at Nomura while the firm downgraded Fifth Third (FITB) to Reduce from Neutral. 4. Myriad Genetics (MYGN) downgraded to Sell from Neutral at Ladenburg with analyst Kevin DeGeeter citing a "significant and unexpected deterioration" in outlook for the company's companion diagnostic franchise. 5. HSN, Inc. (HSNI) downgraded to Hold from Buy at Craig-Hallum with analyst Alex Fuhrman saying his channel checks indicate continued weakness in the third quarter, with particular weakness in jewelry and consumer electronics. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/10/16
CHLM
10/10/16
DOWNGRADE
Target $42
CHLM
Hold
HSN, Inc. downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum analyst Alex Fuhrman downgraded HSN, Inc to Hold and lowered its price target to $42 from $62. Fuhrman's channel checks indicate continued weakness in Q3, with particular weakness in jewelry and consumer electronics. He now estimates net sales to decline 3% year-over-year in Q3 versus his prior estimate for a 1% decline and doesn't expect results to start improving until 2017.
ELNK EarthLink
$5.60

-0.62 (-9.97%)

10/17/16
COWN
10/17/16
INITIATION
Target $8
COWN
Outperform
EarthLink initiated with an Outperform at Cowen
Cowen analyst Jonathan Charbonneau initiated EarthLink with an Outperform and an $8 price target saying he expect stronger revenue trends, stable margins, and another year of meaningful FCF generation in 2017, resulting in multiple expansion.
WIN Windstream
$7.23

-0.01 (-0.14%)

08/05/16
08/05/16
DOWNGRADE

Underperform
Windstream downgraded to Underperform from Market Perform at Raymond James
As previously reported, Raymond James downgraded WIndstream to Underperform from Market Perform. Analyst Frank Louthan said the downgrade is purely based on valuation and believes the fundamental position of Windstream remains strong.
10/13/16
COWN
10/13/16
INITIATION
Target $9
COWN
Market Perform
Windstream initiated with a Market Perform at Cowen
Cowen analyst Gregory Williams initiated Windstream with a Market Perform after completing its tax free spin off of certain telecommunications assets and creating a newly formed publicly traded REIT. Williams has a $9 price target on Windstream shares and believes the shares are fairly valued.
08/05/16
RAJA
08/05/16
DOWNGRADE
RAJA
Underperform
Windstream downgraded to Underperform from Market Perform at Raymond James
10/13/16
COWN
10/13/16
INITIATION
Target $34
COWN
Outperform
Communications Sales & Leasing initiated with an Outperform at Cowen
Cowen analyst Gregory Williams initiated Communications Sales & Leasing (CSAL) with an Outperform rating. Williams cited three components that will drive the majority of value including a superior M&A model, the Windstream (WIN) cash flow generator, and a fiber infrastructure growth engine. Williams has a $34 price target on Communications Sales & Leasing shares.
CHRS Coherus Biosciences
$25.60

-2.55 (-9.06%)

11/07/16
COWN
11/07/16
NO CHANGE
Target $45
COWN
Outperform
Coherus has other paths to pursue in AbbVie patent fight, says Cowen
Cowen analyst Ken Cacciatore noted the U.S. Patent Trial and Appeals Board decided to deny institution of Coherus Biosciences' (CHRS) Inter Partes Review against AbbVie's (ABBV) '166 patent related to Humira, though he believes that Coherus still has other remaining pathways in its patent fight over the drug. "Today's news, although a setback, should be treated as a relatively minor" one, he tells investors. Cacciatore has an Outperform rating and $45 price target on Coherus shares.
11/07/16
COWN
11/07/16
NO CHANGE
COWN
Coherus Biosciences shares defended at Cowen
11/07/16
LEHM
11/07/16
NO CHANGE
LEHM
Coherus Biosciences shares defended at Barclays
11/07/16
SBSH
11/07/16
NO CHANGE
Target $36
SBSH
Buy
Citi says buy Coherus Biosciences on today's selloff
Citi analyst Mohit Bansal recommends using today's selloff in shares of Coherus Biosciences (CHRS) as a buying opportunity. Checks with patent experts indicate that the patent in today's case is not a key obstacle against a biosimilar of AbbVie's Humira, Bansal tells investors in a research note. Further, the analyst estimates fair value of Coherus shares at $24 if the Humira biosimilar is removed completely. The stock is currently down 16%, or $4.60, to $23.55. Basel does not expect a biosimilar launch until 2020. He adds that every one year launch delay post 2020 would impact his fair value for shares by only $1. The analyst keeps a Buy rating on Coherus with a $36 price target.

TODAY'S FREE FLY STORIES

PAYS

Paysign

$11.27

-0.56 (-4.73%)

20:32
11/14/19
11/14
20:32
11/14/19
20:32
Initiation
Paysign initiated  »

Paysign initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 25

    Nov

  • 26

    Nov

LPTX

Leap Therapeutics

$0.57

-0.5922 (-50.83%)

20:25
11/14/19
11/14
20:25
11/14/19
20:25
Downgrade
Leap Therapeutics rating change  »

Leap Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNT

Fortinet

$100.07

0.38 (0.38%)

20:25
11/14/19
11/14
20:25
11/14/19
20:25
Upgrade
Fortinet rating change  »

Fortinet upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 18

    Nov

  • 19

    Nov

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

  • 12

    Dec

JD

JD.com

$33.57

0.21 (0.63%)

, WVE

Wave Life Sciences

$27.90

-0.07 (-0.25%)

20:25
11/14/19
11/14
20:25
11/14/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

JD

JD.com

$33.57

0.21 (0.63%)

WVE

Wave Life Sciences

$27.90

-0.07 (-0.25%)

RYTM

Rhythm Pharmaceuticals

$21.52

0.38 (1.80%)

JCP

J.C. Penney

$1.10

0.01 (0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 09

    Dec

SBS

Sabesp

$12.21

-0.02 (-0.16%)

20:22
11/14/19
11/14
20:22
11/14/19
20:22
Earnings
Sabesp reports Q3 adjusted EBITDA up 109.8% at BRL3.01B »

Reports Q3 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

LINX

Linx S.A.

$7.11

-0.8 (-10.11%)

19:16
11/14/19
11/14
19:16
11/14/19
19:16
Recommendations
Linx S.A. analyst commentary at Jefferies »

Linx S.A. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

CNP

CenterPoint Energy

$26.68

-1.42 (-5.05%)

19:12
11/14/19
11/14
19:12
11/14/19
19:12
Downgrade
CenterPoint Energy rating change at Credit Suisse »

CenterPoint Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$309.54

0.46 (0.15%)

19:09
11/14/19
11/14
19:09
11/14/19
19:09
Periodicals
Kudlow says U.S. near trade agreement with China, Reuters says »

White House economic…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$309.54

0.46 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMRN

BioMarin

$75.55

-0.54 (-0.71%)

18:41
11/14/19
11/14
18:41
11/14/19
18:41
Hot Stocks
BioMarin CEO: Our products have a very long life cycle »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

OXY

Occidental Petroleum

$37.76

-0.36 (-0.94%)

18:38
11/14/19
11/14
18:38
11/14/19
18:38
Periodicals
Judge rejects Icahn's suit seeking Occidental acquisition records, Reuters says »

A Delaware court judge…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTCH

Farfetch

$7.49

-0.54 (-6.72%)

, DGII

Digi International

$15.10

0.33 (2.23%)

18:35
11/14/19
11/14
18:35
11/14/19
18:35
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

FTCH

Farfetch

$7.49

-0.54 (-6.72%)

DGII

Digi International

$15.10

0.33 (2.23%)

AMAT

Applied Materials

$56.89

-0.24 (-0.42%)

KLIC

Kulicke & Soffa

$25.18

-0.22 (-0.87%)

HP

Helmerich & Payne

$39.30

0.04 (0.10%)

WPM

Wheaton Precious Metals

$26.47

-0.12 (-0.45%)

RDNT

RadNet

$15.92

0.09 (0.57%)

RH

RH

$175.19

1.98 (1.14%)

ACB

Aurora Cannabis

$3.29

-0.25 (-7.06%)

OSMT

Osmotica Pharmaceuticals

$4.00

-0.03 (-0.74%)

GLOB

Globant

$108.99

3.975 (3.79%)

DLB

Dolby

$65.56

-0.14 (-0.21%)

NVDA

Nvidia

$209.88

1.33 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 20

    Nov

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

  • 13

    Dec

  • 06

    Jan

VIA

Viacom

$25.31

0.175 (0.70%)

, VIAB

Viacom

$22.48

0.44 (2.00%)

18:24
11/14/19
11/14
18:24
11/14/19
18:24
Hot Stocks
Viacom CEO: The road ahead for the company is very exciting »

In an interview on…

VIA

Viacom

$25.31

0.175 (0.70%)

VIAB

Viacom

$22.48

0.44 (2.00%)

CBS

CBS

$37.62

0.78 (2.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 09

    Dec

NVDA

Nvidia

$209.88

1.33 (0.64%)

18:22
11/14/19
11/14
18:22
11/14/19
18:22
Hot Stocks
Breaking Hot Stocks news story on Nvidia »

Nvidia CFO says continue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

  • 06

    Jan

NVDA

Nvidia

$209.88

1.33 (0.64%)

18:04
11/14/19
11/14
18:04
11/14/19
18:04
Hot Stocks
Nvidia CEO says Q4 will be much stronger driven by AI and inference »

Says computational…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

  • 06

    Jan

BABA

Alibaba

$182.69

0.21 (0.12%)

17:50
11/14/19
11/14
17:50
11/14/19
17:50
Syndicate
Alibaba launches Hong Kong IPO »

Alibaba Group Holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

17:49
11/14/19
11/14
17:49
11/14/19
17:49
Conference/Events
William Blair SaaS analyst to hold a luncheon meeting »

SaaS Analyst Pfau holds a…

HP

Helmerich & Payne

$39.30

0.04 (0.10%)

17:49
11/14/19
11/14
17:49
11/14/19
17:49
Earnings
Helmerich & Payne sees FY20 CapEx approximately $275M-$300M »

57-62% expected for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

PPG

PPG

$129.82

-0.5 (-0.38%)

, PG

Procter & Gamble

$120.49

-0.15 (-0.12%)

17:49
11/14/19
11/14
17:49
11/14/19
17:49
Hot Stocks
Trian Fund exits PPG, cuts Wendy's in Q3 »

Nelson Peltz' Trian…

PPG

PPG

$129.82

-0.5 (-0.38%)

PG

Procter & Gamble

$120.49

-0.15 (-0.12%)

MDLZ

Mondelez

$52.90

0.2 (0.38%)

LM

Legg Mason

$38.60

-0.22 (-0.57%)

GE

General Electric

$11.30

-0.01 (-0.09%)

WEN

Wendy's

$20.90

-0.01 (-0.05%)

BK

BNY Mellon

$48.42

0.07 (0.14%)

SYY

Sysco

$81.51

0.27 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

  • 19

    Nov

  • 19

    Nov

  • 02

    Dec

  • 11

    Dec

  • 16

    Jan

  • 29

    Jan

HP

Helmerich & Payne

$39.30

0.04 (0.10%)

17:48
11/14/19
11/14
17:48
11/14/19
17:48
Earnings
Helmerich & Payne reports Q4 cont ops EPS 38c, consensus 23c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

17:47
11/14/19
11/14
17:47
11/14/19
17:47
Conference/Events
DA Davidson software analysts to hold a dinner meeting »

Analysts host a Security…

MDCO

The Medicines Co.

$50.89

-1.905 (-3.61%)

17:46
11/14/19
11/14
17:46
11/14/19
17:46
Conference/Events
Roth Capital pharmaceuticals analysts to hold a luncheon »

Analysts host Dr. John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

NVDA

Nvidia

$209.88

1.33 (0.64%)

17:44
11/14/19
11/14
17:44
11/14/19
17:44
Hot Stocks
Nvidia CFO says Q3 decline in automotive revenue driven by one-time item »

Says AI cockbit business…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

  • 06

    Jan

CPE

Callon Petroleum

$4.20

-0.265 (-5.94%)

, PSDO

Presidio

$16.56

-0.02 (-0.12%)

17:44
11/14/19
11/14
17:44
11/14/19
17:44
Hot Stocks
Paulson adds Callon Petroleum, lowers stake in Lyft in Q3 »

John Paulson's…

CPE

Callon Petroleum

$4.20

-0.265 (-5.94%)

PSDO

Presidio

$16.56

-0.02 (-0.12%)

OSG

Overseas Shipholding

$1.84

0.045 (2.51%)

STC

Stewart

$43.10

0.11 (0.26%)

AGN

Allergan

$182.47

0.91 (0.50%)

HZNP

Horizon Pharma

$29.82

-0.48 (-1.58%)

ONCE

Spark Therapeutics

$110.78

-0.65 (-0.58%)

MYL

Mylan

$17.26

-0.01 (-0.06%)

S

Sprint

$5.86

-0.21 (-3.46%)

LYFT

Lyft

$41.90

-1.39 (-3.21%)

TMUS

T-Mobile

$76.87

-1.15 (-1.47%)

PCG

PG&E

$6.70

-0.19 (-2.76%)

WCG

WellCare

$301.86

-2.56 (-0.84%)

TSU

Tim Participacoes

$15.53

0.44 (2.92%)

GLD

SPDR Gold Shares

$138.57

0.59 (0.43%)

BHC

Bausch Health

$27.77

0.38 (1.39%)

CELG

Celgene

$110.03

-0.42 (-0.38%)

DISCK

Discovery Inc.

$28.04

0.12 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 07

    Jan

  • 25

    Mar

  • 04

    Apr

17:41
11/14/19
11/14
17:41
11/14/19
17:41
Conference/Events
BTIG energy analysts to hold a luncheon »

Energy Analysts host…

17:40
11/14/19
11/14
17:40
11/14/19
17:40
Conference/Events
Wolfe Research tech strategist to hold analyst/industry webcast »

Tech Strategist…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.